Albert Lowe
Stock Analyst at Craig-Hallum
(2.51)
# 2,300
Out of 5,139 analysts
10
Total ratings
20%
Success rate
16.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Buy | $175 | $82.33 | +112.56% | 1 | Dec 4, 2025 | |
| NGNE Neurogene | Initiates: Buy | $50 | $18.62 | +168.53% | 1 | Jun 17, 2025 | |
| ATOS Atossa Therapeutics | Initiates: Buy | $20 | $4.42 | +352.49% | 1 | Jun 5, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $6 | $3.57 | +68.07% | 1 | Apr 11, 2025 | |
| SKYE Skye Bioscience | Maintains: Buy | $18 → $14 | $0.78 | +1,694.41% | 2 | Mar 21, 2025 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $11 | $3.79 | +190.24% | 1 | Oct 9, 2024 | |
| CRDF Cardiff Oncology | Initiates: Buy | $8 | $1.63 | +390.80% | 1 | Sep 6, 2024 | |
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $4 | $1.78 | +124.72% | 1 | Aug 20, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $6 | $1.07 | +463.38% | 1 | May 13, 2024 |
Palvella Therapeutics
Dec 4, 2025
Initiates: Buy
Price Target: $175
Current: $82.33
Upside: +112.56%
Neurogene
Jun 17, 2025
Initiates: Buy
Price Target: $50
Current: $18.62
Upside: +168.53%
Atossa Therapeutics
Jun 5, 2025
Initiates: Buy
Price Target: $20
Current: $4.42
Upside: +352.49%
Opus Genetics
Apr 11, 2025
Initiates: Buy
Price Target: $6
Current: $3.57
Upside: +68.07%
Skye Bioscience
Mar 21, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $0.78
Upside: +1,694.41%
SAB Biotherapeutics
Oct 9, 2024
Initiates: Buy
Price Target: $11
Current: $3.79
Upside: +190.24%
Cardiff Oncology
Sep 6, 2024
Initiates: Buy
Price Target: $8
Current: $1.63
Upside: +390.80%
Lineage Cell Therapeutics
Aug 20, 2024
Initiates: Buy
Price Target: $4
Current: $1.78
Upside: +124.72%
PMV Pharmaceuticals
May 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.07
Upside: +463.38%